Optimizing drugs to reach treatment targets for children and adolescents living with HIV

Journal of the International AIDS Society

Volumn 18, Issue , 2015, Pages

  Penazzato, Martina ^a   Lee, Janice ^b   Capparelli, Edmund ^c   Essajee, Shaffiq ^a   Ford, Nathan ^a   Ojoo, Atieno ^d   Pascual, Fernando ^e   Sugandhi, Nandita ^f   Lallemant, Marc ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Drugs for Neglected Diseases Initiative   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNICEF   (United States)

^e MEDICINES PATENT POOL   (Switzerland)

^f CLINTON HEALTH ACCESS INITIATIVE   (United States)

Author keywords

Antiretrovirals; ART; Children; Formulations; HIV; Optimization; Treatment

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEW DRUG;

ADOLESCENT; ANTIRETROVIRAL THERAPY; CHILD; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG THERAPY; DRUG USE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATENT; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION; HEALTH CARE PLANNING; HIV INFECTIONS; INFANT; PRESCHOOL CHILD;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; HEALTH PLANNING; HIV INFECTIONS; HUMANS; INFANT;

EID: 84959255220     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.7.20270     Document Type: Review

References (26)

1. UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. 2014 [cited 2015 Sep 22]. Available from: http://www.unaids.org/sites/default/files/media-asset/90-90-90-en-0.pdf
2. Lallemant M, Chang S, Cohen R, Pecoul B. Pediatric HIV - a neglected disease? N Engl J Med. 2011; 365 (7): 581-3. doi: http://dx.doi.org/10.1056/NEJMp1107275
3. iBase. 2014 Pipeline report. [cited 2014 Sep 22]. Available from: http://www. pipelinereport.org/sites/g/files/g575521/f/201407/2014 Pipeline Report Full-0.pdf
4. UNAIDS. 15 by 15 report. 2015 [cited 2015 Sep 22]. Available from: http://www. unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/july/20150714-PR-MDG6reportwww.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS-Gap-report-en.pdf
5. Penazzato M, Bendaud V, Nelson L, Stover J, Mahy M. Estimating future trends in paediatric HIV. AIDS. 2014; 28 (Suppl 4): S445-51. doi: http://dx.doi. org/10.1097/QAD.0000000000000481
6. European Medicines Agency. Article 58 applications: regulatory and procedural guidance. European Medicines Agency. [cited 2015 Sep 22]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl-pages/regulation/document-listing/document-listing-000157.jsp
7. Ponnet M, Frederix K, Petdachai W, Wilson D, Eksaengsri A, Zachariah R. A drug dosage table is a useful tool to facilitate prescriptions of antiretroviral drugs for children in Thailand. Int J STD AIDS. 2005; 16: 420-6.
8. World Health Organization. WHO generic tool for assessing paediatric ARV dosing. [cited 2015 Sep 22]. Available from: http://www.who.int/hiv/paediatric/generictool/en/
9. WHO. Antiretroviral therapy for HIV infection in infants and children: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization; 2010.
10. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infections: recommendations for a public health approach. 2013 [cited 2015 Sep 22]. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/
11. World Health Organization. The annual WHO surveys on the use of ART. [cited 2015 Sep 22]. Available from: http://www.who.int/hiv/pub/amds/amds-arvforecast/en/
12. Global pricing reduction mechanism. WHO. [cited 2015 Sep 22]. Available from: http://www.who.int/hiv/amds/gprm/en/
13. World Health Organization. Paediatric ARV drug optimization 2 meeting report. Geneva, Switzerland: World Health Organization; 2014.
14. World Health Organization. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. [cited 2015 Sep 22]. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/arvs 2013upplement-march2014/en/
15. Holford N, Heo Y, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013; 102 (9): 2941-52.
16. Fillekes Q, Natukunda E, Balungi J, Kendall L, Bwakura-Dangarembizi M, Keishanyu R, et al. Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. J Acquir Immune Defic Syndr. 2011; 58 (4): 392-8. doi: http://dx.doi. org/10.1097/QAI.0b013e318235e560
17. UNITAID/Drugs for Neglected Diseases initiative (DNDi)/Medicines Patent Pool (MPP)/Clinton Health Access Initiative (CHAI). Paediatric HIV treatment initiative (PHTI). [cited 2015 Sep 22]. Available from: http://www.unitaid.eu/en/resources/press-centre/3-news/press/1356-paediatric-hiv-treatment-initiativephti- to-spur-innovation-and-access-to-improve-the-lives-of-children-livingwith- hiv
18. Meeting Report. Update to the optimal list of paediatric ARV formulations. Geneva, Switzerland; 2013 [cited 2015 Sep 22]. Available from: http://www.emtctiatt. org/wp-content/uploads/2014/04/IATT-Sept-2013-Updated-Paediatric-ARTFormulary- Report3.pdf
19. Interagency Task Team on Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Their Children (IATT). Update to the optimal list of paediatric ARV formulations. Geneva, Switzerland; 2015 [cited 2015 Sep 22]. Available from: http://www.emtct-iatt.org/wp-content/uploads/2015/05/Updated-Formulary-04012015.pdf
20. Rainwater-Lovett K, Luzuriaga K, Persaud D. Very early combination antiretroviral therapy in infants: prospects for cure. Curr Opin HIV AIDS. 2015; 10 (1): 4-11. doi: http://dx.doi.org/10.1097/COH.0000000000000127
21. Reisner SL, Mimiaga MJ, Skeer M, Perkovich B, Johnson CV, Safren SA. A review of HIV antiretroviral adherence and intervention studies among HIVinfected youth. Top HIV Med. 2009; 17 (1): 14-25.
22. Davies MA, Moultrie H, Eley B, Rabie H, Van Cutsem G, Giddy J, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa - the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr. 2011; 56 (3): 270-8. doi: http://dx.doi.org/10.1097/QAI.0b013e3182060610
23. Viani RM, Alvero C, Fenton T, Acosta E, Hazra R, O'Gara E, et al. Safety and efficacy of dolutegravir in HIV treatment-experienced adolescents: 48-week results. Presented at 21st Conference on Retroviruses and Opportunistic Infections; Mar 3-6; Boston, MA; 2014.
24. Sax PE, Saag MS, Yin MT, Post FA, Oka S, Koenig E, et al. Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate. 2015 Conference on Retroviruses and Opportunistic Infections (CROI); 2015 Feb 23-26; Seattle, USA; 2015; Abstract 143LB.
25. Wason JM, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med. 2014; 33 (13): 2206-21.
26. K Butler for BREATHER Trial Team. ART with weekends off is non-inferior to continuous ART in young people on EFV-2NRTI. 2015 Conference on Retroviruses and Opportunistic Infections; Feb 23-24; Seattle; 2015. Abstract 38LB.